06/07/2022

Value of Biotech

29/06/2022

EuropaBio’s Vision for Europe: Innovation, Investment, Excellence

27/06/2022

Unlocking the Promise of Gene Therapy

20/06/2022

Seizing opportunities for continued innovation, investment, and excellence in orphan medicines in Europe

25/05/2022

European Week Against Cancer 2022 – Interview with Santiago Aguirre, Market Lead Europe Oncology, Sanofi

23/05/2022

Big Changes Start Small

16/05/2022

EuropaBio Statement on the Evaluation of the Cross-Border Healthcare Directive

25/04/2022

Opinion: A long journey to care, or why it’s time for an ambitious EU framework for a cross-border healthcare

04/04/2022

EuropaBio NAC Summit 2022: key recommendations on how National associations can deliver Europe’s innovation, investment and excellence in biotechnology

28/02/2022

EuropaBio Statement on Rare Disease Day

31/01/2022

EuropaBio becomes a partner of a new European partnership for health

22/12/2021

EuropaBio: Revision of the EU general pharmaceuticals legislation for a healthier tomorrow

13/12/2021

Interview with Ingmar Hoerr, CureVac Founder and holder of the first patents associated with mRNA

EuropaBio sat down with New Member Olon, to find out about their Plans to Expand their Biotechnology Platform.
22/11/2021

The review of the general pharmaceutical legislation: an opportunity that should not be missed?

26/10/2021

Healthy Planet, Healthy People: a Pathway for Green Transition in the Biopharmaceutical Ecosystem

19/10/2021

EuropaBio Patient Bio-Forum: challenges and future potential of European Reference Networks

30/09/2021

Artificial intelligence: investing in new technologies in healthcare

What if machine learning and artificial intelligence could learn to detect one of the most common forms of blood cancer, through evaluating data based on the gene activity of blood cells?
08/09/2021

Treatment Without Borders: The EU Case for Equitable Patient Access to Advanced Therapies

02/08/2021

EuropaBio response to the European Commission Public Consultation on the Regulations for Orphan Medicinal Products and Paediatrics

EuropaBio has responded to the European Commission’s public consultation on the Orphan Medicinal Products (OMPs) and Paediatrics Regulations.
29/07/2021

EuropaBio response to the Public Consultation ‘Digital Health Data and Services – The European Health Data Space’